Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Pharmaceutical

Idorsia

Jean-Paul Clozel

Peter Rooney

Scotty Bowman

Georg Rüedi

Thomas Weller

Eva Caroff

Antonio Olivieri

Julien Gander

Alberto Gimona

Alexander Khatuntsev

Martine Clozel

Olivier Lambert

André C. Muller

Andrew C. Weiss

Guy Braunstein

Markus A. Riederer

The Quality Assurance and Compliance Team at Idorsia is responsible for ensuring that all biopharmaceutical processes adhere to regulatory standards and internal quality protocols. This team conducts audits, monitors compliance with Good Manufacturing Practices (GMP), and oversees data integrity across clinical development to facilitate the safe and effective delivery of innovative treatments. Their collaborative efforts help maintain the integrity of Idorsia's diverse clinical pipeline and promote patient safety across various therapeutic areas.

Quality Assurance and Compliance Team

Leadership Team

Clinical Operations Team

Drug Discovery Team

Quality Assurance and Compliance Team

About

Team members

Other teams at Idorsia

Leadership Team

Clinical Operations Team

Drug Discovery Team